 Kezar Life Sciences Inc NASDAQ: KZR shares are surging in Mondays after-hours session after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib. Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with. 